TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine for Chronic Depression: a Double-blind Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 20 to 75 years (ages 20 to 60 for MRI sub-study)~* diagnosis of dysthymic disorder (chronic depression) or depression NOS~* minimum of 2 years duration of current episode of depression~Exclusion Criteria:~* current major depression~* diagnoses including delirium, dementia, bipolar disorder, schizophrenia~* substance abuse or dependence in the past 6 months~* pregnant or nursing women~* serious risk of suicide

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- duloxetine (cymbalta) (Type: EXPERIMENTAL): Duloxetine medication: a medication currently marketed in the USA that is reported to have pharmacological effects including reuptake blockage for serotonin and norepinephrine
- Placebo treatment (Type: PLACEBO_COMPARATOR): placebo treatment: treatment with placebo capsules that match active medication capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. locally advanced (\>T1) and/or nodal positive (N+) histologically proven adenocarcinoma of the esophagogastreal junction (AEG I-III) or the stomach without distant metastases (M0) and without infiltration of adjacent structures and organs~2. no previous surgical resection~3. no previous cytostatic chemotherapy~4. Age \> 18 years (female and male)~5. ECOG ≤ 2~6. surgical resectability~7. Exclusion of peritoneal carcinomatosis (if clinically suspected) via laparoscopy~8. Leucocytes \> 3.000/µl~9. Platelets \> 100.000/µl~10. Serum creatinin ≤ 1.5x of normal value, or Creatinin-Clearance \> 50 ml/min~11. written informed consent.~12. Ejection fraction \> 50% in echocardiography before start of therapy~Exclusion Criteria:~1. distant metastases or infiltration of adjacent structures or organs and all primarily not resectable stages~2. relapse~3. Hypersensitivity against 5- Fluorouracil, Leucovorin, Oxaliplatin, Cisplatin. Epirubicin and Docetaxel~4. Existence of contraindications against 5- Fluorouracil, Leucovorin, Oxaliplatin, Cisplatin, Epirubicin or Docetaxel~5. Active CHD, Cardiomyopathy or cardiac insufficiency stage III-IV according to NYHA~6. malignant secondary disease, dated back \< 5 years (exception: In-situ-carcinoma of the cervix uteri, adequately treated skin basal cell carcinoma)~7. severe non-surgical accompanying disease or acute infection~8. peripheral polyneuropathy \> NCI Grad II~9. severe liver dysfunction (AST/ALT\>3,5xULN, AP\>6xULN, Bilirubin\>1,5xULN)~10. chronic inflammable gastro-intestinal disease~11. inclusion in another clinical trial~12. pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FLOT (Type: EXPERIMENTAL): Docetaxel 50mg/m2, d1 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (8 weeks) pre-OP and 4 cycles (8 weeks) post-OP
- ECF (Type: ACTIVE_COMPARATOR): Epirubicin 50 mg/m2, d1 Cisplatin 60 mg/m², d1 5-FU 200 mg/m², d1-d21 every 3 weeks (q3w) 3 cycles (9 weeks) pre-OP and 3 cycles (9 weeks) post-OP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants in Groups B and C will be classified by renal function by eGRF at screening and confirmed on Day -1~* Participants in Group A will be healthy participants as determined by no significant deviations in normal medical and surgical history and assessments~* Participants in Group A must have a body mass index of 18.0 to 32.0 kg/m2, inclusive~* Females must be of non-childbearing potential~Exclusion Criteria:~* Participants in Groups B and C cannot have an indwelling catheter for hemodialysis~* Participants in Groups B and C cannot have had, nor be waiting for, an organ transplant~Other protocol defined inclusion and exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Normal Renal Function
- Group B (Type: EXPERIMENTAL): Moderate Renal Impairment
- Group C (Type: EXPERIMENTAL): Severe Renal Impairment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Effectiveness and Safety of Inhaled Corticosteroids and Antimicrobial Compounds for Non-CF Bronchiectasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Within Medicare data, indicated diagnosis of Bronchiectasis by a Pulmonologist (ICD-9 code 494.0 and/or 494.1)~Exclusion Criteria:~* cystic fibrosis diagnosis, HIV infection, history of organ transplant

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non-CF bronchiectasis patients (Type: None): Complete national 2006-2014 Medicare data from Part A, B and D will be obtained from CMS. We will use bronchiectasis ICD-9 codes 494.0 and 494.1 to identify patients with bronchiectasis within Medicare. From this identified bronchiectasis cohort, we will exclude patients with cystic fibrosis (ICD-9 codes 277.00-277.09), HIV infection (042), and a history of organ transplant (V42.0, V42.1, V42.6, V42.7, V42.8).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Marathon and Enduron Polyethylene at Long-Term Follow-up

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~(from original study)~* Elective total hip replacement patient~(from 10-year follow-up)~* Consented to the original study.~* Received a Duraloc 100 cup with either a crosslinked Marathon or standard Enduron liner.~* Received an AML/Solution or a Prodigy stem with 28mm cobalt chrome femoral head.~Exclusion Criteria:~(from original study)~* None~(from 10-year follow-up)~* Patient did not receive device as specified in inclusion criteria.~* Patient refused to consent to continued follow-up.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Crosslinked Marathon polyethylene (Type: ACTIVE_COMPARATOR): The crosslinked Marathon polyethylene liners used for the primary total hip replacements in this study were treated with 5 Mrad (50 kGy) of gamma irradiation to induce crosslinking and then heated above the melting temperature (150 degrees Celsius) to eliminate free radicals. This manufacturing process was designed to improve the polyethylene's resistance to wear through increased crosslinking and eliminate free radicals that render it susceptible to oxidative degradation. These liners were machined and terminally sterilized with gas plasma, a noncrosslinking chemical surface treatment. These liners did not have had free radicals at the time of implantation and did not incorporate antioxidants.
- Noncrosslinked Enduron polyethylene (Type: ACTIVE_COMPARATOR): The standard, noncrosslinked Enduron polyethylene liners used for the primary total hip replacements in this study were manufactured from the same polyethylene resin as the crosslinked Marathon liners but never irradiated. Like the Marathon components, these liners were machined and terminally sterilized with gas plasma, a noncrosslinking chemical surface treatment. Based on the manufacturing methods, these liners would not have had free radicals at the time of implantation and did not incorporate antioxidants.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Montelukast on Difficulty in Breathing After Exercise in Pediatric Patients (MK0476-377)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The child is 4 years to 14 years of age~* The child is a non smoker~* The child has exercise-induced bronchoconstriction (EIB)~Exclusion Criteria:~* The child has active or chronic breathing disease, other than asthma~* The child has required insertion of a breathing tube for asthma~* The child had major surgery within the last 4 weeks~* The child is currently in the hospital~* The child has or had an upper respiratory tract infection within the last 2 weeks~* The child has been hospitalized or visited the emergency room or had a change in their medication for asthma within the last 4 weeks~* The child has been in a research study in the last 4 weeks~* The child has stomach, brain, heart, kidney or liver disease~* The child drinks more that 4 caffeinated drinks a day

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Montelukast Sodium (Type: EXPERIMENTAL): Participants 4-5 years: A single dose of 4 mg Montelukast chewable tablet daily, crossing over to matching placebo (Pbo) after a 3- to 7-day washout period (no participants 4-5 years were enrolled)~Participants 6-14 years: A single dose of 5 mg Montelukast chewable tablet daily, crossing over to matching Pbo after a 3- to 7-day washout period
- Placebo (Type: EXPERIMENTAL): Participants 4-5 years: A single dose of 4 mg Pbo chewable tablet daily, crossing over to Montelukast 4 mg chewable tablet after a 3- to 7-day washout period (no participants 4-5 years of age were enrolled)~Participants 6-14 years: A single dose of 5 mg Pbo chewable tablet daily, crossing over to Montelukast 5 mg chewable tablet after a 3- to 7-day washout period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced solid tumors (excluding SCLC and retinoblastoma) or follicular of diffuse large cell non-Hodgkin's lymphoma, histologically or cytologically proven at diagnosis which is refractory to or intolerant of established therapy know to provide clinical benefit for their condition; tumors must express Rb~* Adequate blood cell counts, kidney function and liver function and and ECOG score of 0, 1, or 2.~* Patients may have to have tumor biopsy before and after treatment.~Exclusion Criteria:~* Prior stem cell or bone marrow transplant~* Uncontrolled infection, unstable or sever intercurrent medical condition, or current drug or alcohol abuse~* Active or unstable cardiac disease or history of heart attack within 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PD-0332991 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent;~* Age of 18 or above;~* Histology confirmed locally advanced unresectable or metastatic triple-negative breaset cancer;~* (KN046 monotherapy) failed at least one prior anthracycline and taxane containing systemic treatment, (KN046 plus nab-paclitaxel) systemic treatment naive;~* Measurable disease at baseline;~* ECOG 0-1;~* Adequate organ functions.~Exclusion Criteria:~* Untreated active CNS metastasis or leptomeningeal metastasis;~* Subjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of trial treatment;~* Has interstitial lung disease, or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management;~* Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent; History of uncontrolled intercurrent illness; Known severe hypersensitivity reactions to antibody drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KN046 (Type: EXPERIMENTAL): Subjects will receive KN046 at a dose of 3 mg/kg or 5 mg/kg via intravenous infusion on Days 1 and 15 of every 28-day cycle until disease progression, unacceptable toxicity or completion of 2 years of treatment
- KN046 plus nab-paclitaxel (Type: EXPERIMENTAL): Subjects will receive KN046 at a dose of 3 mg/kg or 5 mg/kg via intravenous infusion on Days 1 and 15 of every 28-day cycle until disease progression, unacceptable toxicity or completion of 2 years of treatment Subjects will receive nab-paclitaxel at a dose of 100 mg/m2 via intravenous infusion on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects aged between and including 18 and 45 years at time of Visit 1~2. Subjects willing to give written informed consent to participate in the trial~3. Subjects who are healthy as determined by medical history, with no clinically significant abnormalities in clinical examination and laboratory tests~Exclusion Criteria:~1. Subjects unwilling to give his/her consent to participate in the trial~2. Subjects who have received Typhoid containing vaccines~3. Subjects who have past history of Typhoid~4. Subjects already immunized with any licensed vaccine within 4 weeks~5. Subjects with known hypersensitivity to any component of the study vaccine~6. Subjects who are pregnant, lactating or childbearing age not using a reliable method of contraception~7. Subjects with any abnormality or chronic disease~8. Subjects with evidence of acute illness within past 7 days requiring systemic antibiotic or antiviral therapy~9. Subjects who have experienced transient thrombocytopenia or neurological complications following an earlier immunization against diphtheria and/or typhoid~10. Subjects who have known history of immune function disorders~11. Subjects who have known history of administration of blood or blood-derived products~12. Subjects who have history of alcohol or substance abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Test group (Type: EXPERIMENTAL): Single dose of EuTCV will be administered intramuscularly
- Comparator group 1 (Type: ACTIVE_COMPARATOR): Single dose of Typbar-TCV™ will be administered intramuscularly
- Comparator group 2 (Type: ACTIVE_COMPARATOR): Single dose of Typhim Vi® will be administered intramuscularly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be a Veteran~* Diagnosis of psychotic disorders, schizophrenia, schizoaffective disorder and bipolar illness~* Age 18-70~* Clinically determined to require ongoing treatment with Second Generation Antipsychotics (SGA) such as olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole, clozapine~* Experienced weight gain since treatment with SGA's~* Inpatient or outpatient at the West Los Angeles VA~* Competent to sign informed consent~Exclusion Criteria:~* Have recently been diagnosed with schizophrenia (less than 1 year)~* Are pregnant or breast feeding a baby~* Have a medically unstable condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Usual Care (Type: NO_INTERVENTION): Usual Care
- Lifestyle Balance (Type: ACTIVE_COMPARATOR): Behavioral Weight Loss Program

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have documented rheumatoid arthritis with a duration of at least 3 months as determined by the investigator using standardly accepted criteria, must have been receiving methotrexate for at least 3 months to treat their rheumatoid arthritis, and must be free of any signs or symptoms of infection.~Exclusion Criteria:~* Subjects cannot enter the study if they have recently received treatment with certain medications which might interfere with study medications;~* subjects cannot enter if they have abnormalities in certain blood tests, history of cancer, recent bone fracture or other significant conditions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-04171327 1 mg QD (Type: EXPERIMENTAL): None
- PF-04171327 5 mg QD (Type: EXPERIMENTAL): None
- PF-04171327 10 mg QD (Type: EXPERIMENTAL): None
- PF-04171327 15 mg QD (Type: EXPERIMENTAL): None
- prednisone 5 mg QD (Type: ACTIVE_COMPARATOR): None
- prednisone 10 mg QD (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Subcutaneous Rehydration With Recombinant Human Hyaluronidase for Infants and Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Child, 2 months to 10 years of age~* Body weight less than 42 kg~* Presenting at emergency department with mild to moderate dehydration (Gorelick dehydration classification: presence of 1 to 6 \[of possible 10\] moderate or severe signs and symptoms) requiring parenteral rehydration~Exclusion Criteria:~* In shock or life-threatening situation (other than dehydration)~* Severe dehydration~* Requires intravenous (IV) therapy for another indication~* Indwelling IV catheter (excepting one intended strictly for clinical laboratory sample collection)~* Already received rehydration therapy IV within prior 48 hours or substantial oral fluid immediately before enrollment~* Condition precluding subcutaneous injection or infusion site evaluation in anterior thigh or other elected infusion site~* Reason for hospital admission or extended emergency department stay other than dehydration~* Known hypersensitivity to hyaluronidase or another ingredient in HYLENEX~* Hyponatremia or hypernatremia~* Hypokalemia~* Medical condition likely to interfere with ability to fully complete study or have protocol-specified assessments~* Medical history, screening examination finding or historical clinical laboratory result precluding safe participation in study or which might adversely effect interpretation of study results~* Participated in study of any investigational drug or device within 30 days prior to this study

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- HYLENEX-augmented subcutaneous (SC ) rehydration (Type: EXPERIMENTAL): Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Use of Somatropin in Patients Small for Gestational Age

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients need to be administered Somatropin (Genotropin®) in order to be enrolled in the surveillance.~Exclusion Criteria:~* Patients not administered Somatropin (Genotropin®).

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Somatropin (Type: None): Patients administered Somatropin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete